| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | 1 | Y | 1 Ramucirumab + Paclitaxel | 94 | 18 | 3 | 2 | 0 | 0 | 0 | 06/01/2020 | 166 | 55 |
| 2 FOLFIRI | 16 | 2 | 2 | 2 | 0 | 0 | ||||||||
| 34 | 5 | 4 | 2 | 0 | 0 | |||||||||
| S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | 1 | Y | 1 Olaparib + Pembrolizumab | 88 | 26 | 6 | 5 | 4 | 2 | 0 | 02/22/2021 | 172 | 72 | |
| 2 Olaparib | 28 | 10 | 3 | 3 | 1 | 0 | ||||||||
| 54 | 16 | 8 | 7 | 3 | 0 | |||||||||
| S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | 1 | Y | 1 Capecitabine Temozolomide | 154 | 31 | 19 | 9 | 5 | 0 | 0 | 05/05/2022 | 181 | 59 | |
| 2 Observation | 16 | 8 | 4 | 1 | 0 | 0 | ||||||||
| 47 | 27 | 13 | 6 | 0 | 0 | |||||||||
| S2107-Colorectal, BRAF mut, Enc + CET +/-Nivo | 1 | Y | 1 Nivolumab + Encorafenib + Cetuximab | 84 | 47 | 30 | 17 | 10 | 3 | 0 | 07/19/2022 | 170 | 67 | |
| 2 Encorafenib Cetuximab | 27 | 14 | 7 | 3 | 2 | 0 | ||||||||
| 74 | 44 | 24 | 13 | 5 | 0 | |||||||||
| S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | 1 | Y | 2 Paclitaxel + Ramucirumab | 224 | 1 | 1 | 1 | 1 | 0 | 0 | 06/24/2024 | 127 | 41 | |
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| Yes | A021806-Pancreas, Perioperative vs Adjuvant Chemo | 0 | E | Total Registrations | 36 | 9 | 2 | 1 | 0 | 0 | 10/08/2020 | 270 | 121 | |
| 36 | 9 | 2 | 1 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 30 | 8 | 2 | 1 | 0 | 0 | 10/08/2020 | |||||
| 30 | 8 | 2 | 1 | 0 | 0 | |||||||||
| A022001-PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM | 1 | E | Total Registrations | 2 | 1 | 0 | 0 | 0 | 0 | 06/08/2023 | 59 | 27 | ||
| 2 | 1 | 0 | 0 | 0 | 0 | |||||||||
| A022004-Colon, Stg II-III, Encor+Cetux vs SOC | 0 | E | Total Registrations | 10 | 10 | 10 | 7 | 4 | 3 | 03/06/2024 | 15 | 9 | ||
| 10 | 10 | 10 | 7 | 4 | 3 | |||||||||
| A022102-Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo | 1 | E | Total Registrations | 19 | 17 | 13 | 9 | 4 | 2 | 05/15/2023 | 233 | 92 | ||
| 19 | 17 | 13 | 9 | 4 | 2 | |||||||||
| A022104-Rectal, Loc Adv, Triplet vs Doublet Chemo | 1 | E | Total Registrations | 62 | 56 | 26 | 11 | 2 | 0 | 03/13/2023 | 344 | 133 | ||
| 62 | 56 | 26 | 11 | 2 | 0 | |||||||||
| EA2174-Esoph, Peri-Op Nivolumab +/- Ipilimumab | 1 | E | Total Registrations | 6 | 0 | 0 | 0 | 0 | 0 | 06/01/2021 | 239 | 91 | ||
| 6 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 3 | 0 | 0 | 0 | 0 | 0 | 06/01/2021 | |||||
| 3 | 0 | 0 | 0 | 0 | 0 | |||||||||
| EA2192-Panc, APOLLO | 0 | E | Total Registrations | 4 | 2 | 0 | 0 | 0 | 0 | 12/07/2022 | 153 | 85 | ||
| 4 | 2 | 0 | 0 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 2 | 1 | 0 | 0 | 0 | 0 | 12/07/2022 | |||||
| 2 | 1 | 0 | 0 | 0 | 0 | |||||||||
| NRGGI008-Colon, Stg III, Adj Chemo | 1 | E | Total Registrations | 31 | 19 | 9 | 4 | 2 | 0 | 12/08/2022 | 418 | 175 | ||
| 31 | 19 | 9 | 4 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 21 | 14 | 7 | 3 | 0 | 0 | 12/08/2022 | |||||
| 21 | 14 | 7 | 3 | 0 | 0 | |||||||||
| No | A022101-Colorectal, Metastatic, Ablative Tx | 0 | E | Total Registrations | 1 | 1 | 1 | 1 | 1 | 0 | 07/12/2024 | 1 | ||
| 1 | 1 | 1 | 1 | 1 | 0 | |||||||||
| CCTGCO32-Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 1 | 0 | 06/26/2024 | 1 | |||
| 1 | 1 | 1 | 1 | 1 | 0 | |||||||||
| CCTGNE1-Midgut NET, Unresect, 177 Lut vs Ever | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 0 | 0 | 06/11/2024 | ||||
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| EA2176-Anal, Met, Immune Check Pt Inhibition + Chemo | 1 | E | Total Registrations | 32 | 13 | 7 | 3 | 1 | 0 | 08/09/2021 | 224 | 89 | ||
| 32 | 13 | 7 | 3 | 1 | 0 | |||||||||
| EA2182-Anal, Erly, DECREASE | 0 | E | Total Registrations | 13 | 6 | 1 | 1 | 0 | 0 | 05/04/2022 | 300 | 97 | ||
| 13 | 6 | 1 | 1 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 14 | 6 | 1 | 1 | 0 | 0 | 05/04/2022 | |||||
| 14 | 6 | 1 | 1 | 0 | 0 | |||||||||
| EA2197-Gal, Rando Perioperative TX | 1 | E | Total Registrations | 7 | 3 | 2 | 2 | 1 | 0 | 11/18/2021 | 134 | 69 | ||
| 7 | 3 | 2 | 2 | 1 | 0 | |||||||||
| EA2222-Colorectal, Stg II-III, Hep Art Infusion | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 0 | 0 | 06/12/2024 | 1 | |||
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| EAY191A6-Biliary Tract, Adv, FOLFOX+Bin | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 1 | 0 | 07/18/2024 | ||||
| 1 | 1 | 1 | 1 | 1 | 0 | |||||||||
| NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy | 1 | Y | Total Registrations | 15 | 0 | 0 | 0 | 0 | 0 | 04/18/2018 | 323 | 118 | ||
| 15 | 0 | 0 | 0 | 0 | 0 | |||||||||
| NRGGI005-COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy | 1 | Y | Total Registrations | 35 | 0 | 0 | 0 | 0 | 0 | 07/06/2020 | 435 | 162 | ||
| 35 | 0 | 0 | 0 | 0 | 0 | |||||||||
| NRGGI006-Esophagus, Stg I-IVA, PBT vs IMRT | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 0 | 0 | 06/21/2024 | ||||
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 1 | 1 | 1 | 1 | 0 | 0 | 06/21/2024 | |||||
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| A022004 Colon, Stg II-III, Encor+Cetux vs SOC | 1 Registration | 30-May-23 | 15 | 9 |
| A022101 Colorectal, Metastatic, Ablative Tx | 1 Registration | 10-Jan-23 | 1 | |
| NRGGI008 Colon, Stg III, Adj Chemo | 3 Randomization | 10-Mar-22 | 418 | 175 |